DGAP-News: NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
NIH awards major contract to Evotec to Manage and Operate a Small
Molecule Repository
19.09.2012 / 07:29
---------------------------------------------------------------------
* NIH Small Molecule Repository
Hamburg, Germany - 19 September 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that Evotec has entered into a multi-year
compound management agreement with the National Institutes of Health (NIH),
Department of Health and Human Services, for the operation of a Small
Molecule Repository. The contract (funded in its entirety by NIH) covers a
period of up to ten years and has a total estimated value of up to EUR 60
million (approx. USD 75 million).
The NIH Small Molecule Repository (SMR) contract will continue to provide
services initiated previously under contract N01MH41001 to acquire, store,
maintain, and distribute the current library collection, supporting certain
NIH-supported screening Centers conducting high-throughput screening (HTS)
for probe and drug discovery. As part of continuing efforts to expand and
support translational science, this contract resource will now be made
available to select outside collaborators (in addition to the NIH screening
efforts/programs). Library development efforts will continue to shape,
improve, and expand the collection.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'We are
delighted the NIH has elected to award Evotec this long term contract which
further validates our entry into compound management through our
acquisition of Compound Focus Inc. in June 2011. This long term contract
will be managed through our San Francisco subsidiary however we are also
currently developing options to expand our compound management capabilities
into the East Coast of USA and also into Europe.'
About the NIH Small Molecule Repository
The NIH Small Molecule Repository, initiated in 2004, was developed as part
of the Molecular Libraries Program, an NIH Common Fund Initiative. The
goals of the SMR are to identify, acquire, maintain, and distribute a
collection of chemically diverse compounds with known and unknown
biological activities for use in high-throughput screening (HTS). These
compounds are intended to serve as starting material for the development of
chemical probes to explore basic biology, as well as leads for therapeutics
development.
FORWARD LOOKING STATEMENTS - Information set forth in this press
release contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained herein
represent the judgement of Evotec as of the date of this report. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
19.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
185715 19.09.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="CuOro Reports Positive Preliminary Metallurgical Test Results of 94.6% Copper and 97% Gold Recoveries at Santa Elena ProjectDatum: 19.09.2012 - 07:29 Uhr
Sprache: Deutsch
News-ID 184658
Anzahl Zeichen: 6611
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
